Sialic acid cis-ligand dynamics modulate Siglec-7 and -9 function and affect Siglec-7/9 co-blockade to potentiate natural killer cell anti-tumor activity - PubMed
4 hours ago
- #NK cell therapy
- #cancer immunotherapy
- #glyco-immune checkpoint
- Siglec-7 and -9 are glyco-immune checkpoints targeted in cancer immunotherapy.
- Cis-ligand interactions on immune cells inhibit trans-signaling induced by tumor cells.
- Co-blockade of both Siglec-7 and -9 enhances NK cell anti-tumor activity more than single blockade.
- Removing cis-ligands with sialidase further boosts NK cell killing of melanoma and AML cells.
- NK cell activation or proliferation downregulates Siglec-7 and -9 cis-ligand expression.
- Siglec-7/9 co-inhibition is key for clinical applications and next-generation immunotherapy design.